BTG3 and ovarian cancer: A body of evidence indicates that BTG3 expression is down-regulated in gastric cancer (Gou et al., 2015; Ren et al., 2015), esophageal adenocarcinoma (Du et al., 2015), hepatocellular carcinoma (Lv et al., 2013), lung cancer (Chen et al., 2013), ovarian cancer (Deng et al., 2013), renal cell carcinoma (Majid et al., 2009), and colorectal cancer (Xiong et al., 2017) due to its promoter methylation (Yu et al., 2008; Majid et al., 2009; Lv et al., 2013; Gou et al., 2015), in line with our findings about lung and breast cancers.